Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSRT + Anlotinib in Recurrent High-Grade Glioma
NCT04197492Phase 2Active, not recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in glioma, sponsored by Huashan Hospital. Primary endpoint: Overall Survival at 24 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04197492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197492.